JP2020504135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504135A5 JP2020504135A5 JP2019536859A JP2019536859A JP2020504135A5 JP 2020504135 A5 JP2020504135 A5 JP 2020504135A5 JP 2019536859 A JP2019536859 A JP 2019536859A JP 2019536859 A JP2019536859 A JP 2019536859A JP 2020504135 A5 JP2020504135 A5 JP 2020504135A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 178
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 20
- 210000004072 lung Anatomy 0.000 claims description 8
- 210000003979 eosinophil Anatomy 0.000 claims description 7
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000000440 neutrophil Anatomy 0.000 claims description 6
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 4
- 238000001764 infiltration Methods 0.000 claims description 4
- 201000004193 respiratory failure Diseases 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000034309 Bacterial disease carrier Diseases 0.000 claims description 2
- 239000002028 Biomass Substances 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 230000007883 bronchodilation Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 230000005713 exacerbation Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 230000003434 inspiratory effect Effects 0.000 claims description 2
- 230000002427 irreversible effect Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 43
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 40
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443591P | 2017-01-06 | 2017-01-06 | |
| US62/443,591 | 2017-01-06 | ||
| PCT/US2018/012694 WO2018129400A1 (en) | 2017-01-06 | 2018-01-05 | Methods and compositions for treating chronic obstructive pulmonary disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020504135A JP2020504135A (ja) | 2020-02-06 |
| JP2020504135A5 true JP2020504135A5 (enExample) | 2021-02-12 |
Family
ID=62790958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536859A Pending JP2020504135A (ja) | 2017-01-06 | 2018-01-05 | 慢性閉塞性肺障害を処置するための方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190338027A1 (enExample) |
| EP (1) | EP3565597A4 (enExample) |
| JP (1) | JP2020504135A (enExample) |
| WO (1) | WO2018129400A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4014995A1 (en) | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| US10774145B2 (en) | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
| US10604577B2 (en) | 2015-10-22 | 2020-03-31 | Allakos Inc. | Methods and compositions for treating systemic mastocytosis |
| EA201992626A1 (ru) | 2017-05-05 | 2020-04-24 | Аллакос Инк. | Способы и композиции для лечения аллергических заболеваний глаз |
| MX2022001403A (es) * | 2019-08-02 | 2022-03-25 | Allakos Inc | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2431834T3 (es) * | 2000-03-07 | 2013-11-28 | The Johns Hopkins University | Anticuerpos de sialoadhesina factor-2 |
| SMT201900714T1 (it) * | 2013-12-09 | 2020-01-14 | Allakos Inc | Anticorpi anti-siglec-8 e loro metodi d'impiego |
| EP4014995A1 (en) * | 2014-02-28 | 2022-06-22 | Allakos Inc. | Methods and compositions for treating siglec-8 associated diseases |
| US10774145B2 (en) * | 2015-06-17 | 2020-09-15 | Allakos Inc. | Methods and compositions for treating fibrotic diseases |
-
2018
- 2018-01-05 EP EP18736183.7A patent/EP3565597A4/en not_active Withdrawn
- 2018-01-05 WO PCT/US2018/012694 patent/WO2018129400A1/en not_active Ceased
- 2018-01-05 US US16/476,027 patent/US20190338027A1/en not_active Abandoned
- 2018-01-05 JP JP2019536859A patent/JP2020504135A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024150751A5 (enExample) | ||
| JP2020504135A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| US11597768B2 (en) | Immunotherapy for hepatocellular carcinoma | |
| JP2017514461A5 (enExample) | ||
| JP2013538553A5 (enExample) | ||
| JP2017507945A5 (enExample) | ||
| JP2018527887A5 (enExample) | ||
| JP2018535648A5 (enExample) | ||
| JP2017534577A5 (enExample) | ||
| JP2008511542A5 (enExample) | ||
| JP2016533335A5 (enExample) | ||
| JP2012504634A5 (enExample) | ||
| RU2011117237A (ru) | АНТИТЕЛА ПРОТИВ Notch2 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018525332A5 (enExample) | ||
| JP2009533367A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2019513726A5 (enExample) | ||
| JPWO2021217004A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2018533569A5 (enExample) | ||
| BR112020017445A2 (pt) | anticorpos anti cd6 para tratar asma severa | |
| TWI834254B (zh) | α-烯醇酶拮抗劑治療纖維化疾病之用途 | |
| JP2013507962A5 (enExample) | ||
| JP2016537965A5 (enExample) |